Michael R. Megna - 15 Jul 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF ACCOUNTING OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
15 Jul 2023
Net transactions value
-$17,387
Form type
4
Filing time
06 Sep 2023, 19:08:34 UTC
Previous filing
11 Apr 2023
Next filing
06 Oct 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Award $7,175 +581 +4.5% $12.35 13,558 15 Jul 2023 Direct F1
transaction KNSA Class A Common Share Options Exercise +3,933 +29% 17,491 01 Sep 2023 Direct F2
transaction KNSA Class A Common Share Tax liability $20,513 -1,155 -6.6% $17.76 16,336 01 Sep 2023 Direct
transaction KNSA Class A Common Share Options Exercise +774 +4.7% 17,110 02 Sep 2023 Direct F2
transaction KNSA Class A Common Share Tax liability $4,049 -228 -1.3% $17.76 16,882 02 Sep 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -3,933 -25% $0.000000 11,797 01 Sep 2023 Class A Common Share 3,933 Direct F2, F3
transaction KNSA Restricted Share Unit Award $0 +10,230 $0.000000 10,230 01 Sep 2023 Class A Common Share 10,230 Direct F2, F4
transaction KNSA Share Option Award $0 +20,459 $0.000000 20,459 01 Sep 2023 Class A Common Share 20,459 $17.76 Direct F5
transaction KNSA Restricted Share Unit Options Exercise $0 -774 -33% $0.000000 1,549 02 Sep 2023 Class A Common Share 774 Direct F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2023 to July 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
F2 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F3 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.
F4 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.
F5 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
F6 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021.